debbie.maierhofer@tolmar.comand+1-4129158447 Protocol No.: NA Center No.: Subject Id: 24.REPORT NULLIFIED YES DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER Protocol No.: NA Center No.: Subject Id:																					
1. PATIENT INITIALS 1a. COUNTRY DOMINICAN	SUSI	PECT ADVERSI	E REACTI	ON REPOR	RT																
I. PATENT INITIALS 1a. COUNTRY 2 DATE OF BIRTH 2a. AGE 3. SEX 4-0 REACTION CONSET 5-12 CHECK ALL 7-13 DESCRIBE REACTION(S) encluding relevant tosts/slub data) 10 Death (Doath (10011906)) 10 Death (10011906) 10 Death (10011	DO-Tolmar-TLM-202	25-00150																			
I. PATENT INITIALS 1a. COUNTRY 2 DATE OF BIRTH 2a. AGE 3. SEX 4-0 REACTION CONSET 5-12 CHECK ALL 7-13 DESCRIBE REACTION(S) encluding relevant tosts/slub data) 10 Death (Doath (10011906)) 10 Death (10011906) 10 Death (10011					I RFAC	TION	INFORI	MATION													
MMC DOMINICAN Day Month Year 29 Sep 19339 B4 Male Day Month Year TO ADVERSE REACTIONS (Including relevant testafilial data) 7-13 DESCRIBE REACTION(6) (Including relevant testafilial data) 1) Death (Death (10011906), Death (10011906)) Fatal 2) High PSA (Prostatic specific antigen increased (10036975), Prostatic specific antigen increased (10036975)) Recovering/Resolving II. SUSPECT DRUG(S)INFORMATION II. SUSPECT DRUG(S)INFORMATION II. SUSPECT DRUG(S)INFORMATION III. SUSPECT DRUG(S) ADMINISTRATION III. CONCOMITANT DRUG(S) ADMINISTRATION III. CONCOMITANT DRUG(S) AND HISTORY III. CONCOMITANT DR		1a. COUNTRY	2. DATE O	F BIRTH	1.112/10				4-6 RE	ACTI	ION OI	NSE	Т		T	8-12	CHE	CK AL	L		_
The property of the property	' '	DOMINICAN	Day	Month	Year	I		Male	Day Month Year				'ear			TO A	DVER	SE			
PATIENT DIED	MMC		1	Sep	1939	'	84	Iviale									REAC	NOIT			
1) Deaft (Death (10011906), Death (10011906)) Fatal 2) High PSA (Prostatic specific antigen increased (10036975)), Prostatic specific antigen increased (10036975)) Recovering/Resolving	7+13 DESCRIBE REA		l ng relevant t	ests/lab data)	ļ			<u> </u>								DATIE	ENIT DIE	=D		
2) High PSA (Prostatic specific antigen increased (10036975)) Recovering/Resolving Recovering Recoverin		011906), Death	(1001190	3))																	
Recovering/Resolving Cont. Cont.		atic specific antic	nen increas	sed (100369	975) Prosta	atic so	ecific a	ntigen inc	reased	(10	03697	75))				Ш				NG	
Cont. RESULTS IN RESULTS	, , ,		3011 1110100	,	<i>510)</i> , 1100ta	atio op	oomo a	inagon me	, oacoa	(10		(0))					PROL	ONGE	D INF		ΙT
II. SUSPECT DRUG(S)INFORMATION III. SUSPECT DRUG(S)INFORMATION III. SUSPECT DRUG(S)(include generic name) 1) Eligard® (Leuprolide acetate) Injection, 22.5 milligram (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) 20. DID EVENT ABATE AFTER ABATE ATTER ABATE ATTER ABATE AFTER ABATE ATTER ABATE ATTER ABATE ATTER ABATE ABATE ABATE ATTER ABATE ABATE ATTER ABATE ABATE ATTER ABATE ABATE ATTER														Cor	nt	П	RESU	JLTS IN			
II. SUSPECT DRUG(S)(include generic name) II. SUBCULTORUG(S)(include generic name) II. SUBCULTORUG(S)(include acetate) Injection, 22.5 milligram (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) Cont.																ш	SIGNI	IFICAN [®]	Т		Y
II. SUSPECT DRUG(S)(Include generic name) 1) Eligard® (Leuprolide acetate) Injection, 22.5 milligram (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) Cont. 15. DAILY DOSE(S) 15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION 1) Subcutaneous 2) Subcutaneous 3. In it is a Month 17. INDICATION(S) FOR USE 19. THERAPY DURATION 119. THERAPY DURATION 110. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) Candelsal 2.5 Cont. 22. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA 4ebbie. maierhofer@tolmar.comand+1-4129158447 DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER STUDY																CONGENITAL ANOMALY					Y
II. SUSPECT DRUG(S)INFORMATION 14. SUSPECT DRUG(S)(include generic name) 1) Eligard® (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) 20. DID EVENT ABATE AFTER STOPPING BRUG? 15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION 10. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 1) Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 14. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 3 Month) 13. Subcutaneous 21. DID EVENT REAPPEAR AFTER STOPPING BRUG? 12. Smilligram(s), 1 in 5. Smilligram(s), 1																П					NI.
14. SUSPECT DRUG(S)(include generic name) 1) Eligard® (Leuprolide acetate) (njection, 22.5 milligram (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) 20. DID EVENT ABATE AFTER STOPPING DRUG? 16. ROUTE(S) OF ADMINISTRATION 1) Subcutaneous 16. ROUTE(S) OF ADMINISTRATION 1) Subcutaneous 20. DID EVENT REAPPEAR AFTER STOPPING DRUG? 10. DID EVENT REAPPEAR AFTER STOPPING DRUG. 10. DID EVENT REAPPEAR AFTER																	IIVIPO	KIANI	CON	וטוווטו	N .
1) Eligard® (Leuprolide acetate) Injection, 22.5 milligram (Leuprolide acetate) (Leuprolide acetate) (Suspect) (Injection) Cont. 15. DAILY DOSE(S) 15. DAILY DOSE(S) 17. INDICATION(S), 1 in 3 Month) 19. Subcutaneous 2) (22.5 milligram(s), 1 in 3 Month) 17. INDICATION(S) FOR USE 19. Prostate cancer [100060862 - Prostate cancer] 18. THERAPY DATE(S) (from/to) 11. (DAI/Dec/2023 -) 11. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 11. CANCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 11. PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont. 12. INDICATION(S) FOR USE 19. THERAPY DURATION 11. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 11. CANCOMITANT DRUG(S) AND HISTORY 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 11. PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont. 12. INDICATION(S) FOR USE 11. NA Applicable) 12. NO APPLICATION (NA INDICATION) 12. CONCOMITANT DRUG(S) AND HISTORY 25. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 11. PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont. 12. NAME AND ADDRESS OF MANUFACTURER 12. NAME AND ADDRESS OF MANUFACTURER 24. NAME AND ADDRESS OF MANUFACTURER 25. Study Name: NA EudraCT Number: Protocol No: NA Center No: Subject Id: 24. REPORT NULLIFIED 24. MFR CONTROL NO. 25. DOT-Iolmar-TLM-2025-00150 26. DATE RECEIVED 26. MFR CONTROL NO. 26. DATE RECEIVED 26. MFR CONTROL NO. 27. STUDY LITERATURE 26. REPORT TUPE 26. REPORT TUPE	LA QUODEOT DDUO	2)/: 1 1		II.	SUSPECT	DRU	G(S)INI	FORMAT	ION						- Ia		DID 5	- /E N 17			
15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION 17. INDICATION(S), 1 in 3 Month) 19. Subcutaneous 19. Subcutaneous 19. Subcutaneous 19. THERAPY DURATION 19. THERAPY D	,	, . ·	,	milligram (l euprolide a	acetat	e) (Leu	prolide ad	cetate) ((Sus	spect)	(Inie	ectio	n)	2	20.	ABAT	E AF1	ΓER		
15. DAILY DOSE(S) 10. (22.5 milligram(s), 1 in 3 Month) 21. (22.5 milligram(s), 1 in 3 Month) 22. (22.5 milligram(s), 1 in 3 Month) 23. Subcutaneous 24. REPORT NULLIFIED 24. REPORT NULLIFIED 24. REPORT SUDAY 25. DAILY DOSE(S) 27. DID EVENT 27. DID EVENT 28. APPER RAFTER RAT	.,ga. as (_sap.s.	.uo uootato, ii jo	0,	g (acciai	0) (200	p. 0a0 a.	otato, ((00.0	op cou	()	000	,	ıt		1				
1) (22.5 milligram(s), 1 in 3 Month) 2) (23.5 milligram(s), 1 in 3 Month) 2) (24.5 milligram(s), 1 in 3 Month) 2) (25.5 mi	15. DAILY DOSE(S)					1.	16. ROL	JTE(S) OF	ADMINI	STR	ATION	1				 21.	_			135_1	NA
2) (22.5 milligram(s), 1 in 3 Month) 2) Subcutaneous	1) (22.5 milligram(s)	, 1 in 3 Month)					,	Subcutaneous									REAF AFTE	PEAF	₹		
17. INDICATION(S) FOR USE 11 Prostate cancer [10060862 - Prostate cancer] 18. THERAPY DATE(S) (from/to) 11 (04/Dec/2023 -) III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) Candelsal 2.5 Cont 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24. REPORT NULLIFIED 24. PROST SOURCE BY MANUFACTURER OD-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE HEALTH PROFESSIONAL DATE OF THIS REPORT 25a. REPORT TYPE						2	2) Subo	ocutaneous								REINTRODUCTION					
17. INDICATION(S) FOR USE 1) Prostate cancer [10060862 - Prostate cancer] 18. THERAPY DATE(S) (from/to) 1) (04/Dec/2023 -) III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1)Candelsal 2.5 Cont 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION Alan NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24. REPORT NULLIFIED YES NO DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE HEALTH PROFESSIONAL DATE OF THIS REPORT 25a. REPORT TYPE		,														(N		t Apr	NO Nico		NA
18. THERAPY DATE(S) (from/to) 1) (04/Dec/2023 -) III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) Candelsal 2.5 Cont 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 Center No.: Subject Id: 24. REPORT NULLIFIED 24b. MFR CONTROL NO. 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE HEALTH PROFESSIONAL DATE OF THIS REPORT 25a. REPORT TYPE	` '		tata canca	rl											\exists	(14)	A . NC	и Арр	лса	oie)	
1) (04/Dec/2023 -) III. CONCOMITANT DRUG(S) AND HISTORY	,		state Carice		APY DURAT	ION									\dashv						
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 1) Candelsal 2.5 Cont 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION Study Information Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id: 24b. MFR CONTROL NO. DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER STUDY LITERATURE USABALT PROFESSIONAL DATE OF THIS REPORT 25a. REPORT TYPE	· ·	, (
1)Candelsal 2.5 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) V. MANUFACTURER INFORMATION				III. Co	ONCOMITA	NT DI	RUG(S) AND HI	STORY												
Cont 23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24. REPORT NULLIFIED 24b. MFR CONTROL NO. DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE		RUG(S) AND DAT	ES OF ADM	IINISTRATIO	N (exclude th	nose us	sed to tre	eat reaction	٦)												_
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 EudraCT Number: Protocol No.: NA Center No.: Subject Id: 24b. MFR CONTROL NO. YES NO DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE	1)Candelsal 2.5																			Con	nt
1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes) Cont IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24b. MFR CONTROL NO. 24c. DATE RECEIVED BY MANUFACTURER DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE	23 OTHER RELEVANT	T HISTORY (a.g.	liagnostics	allergies pre	anancy with I	aet mo	nth of no	ariod etc.)												001	
IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24b. MFR CONTROL NO. 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id:			-				illii oi pe	eriou, etc.)													
24a. NAME AND ADDRESS OF MANUFACTURER Name: Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24.REPORT NULLIFIED 24b. MFR CONTROL NO. 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id: 3tudy Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id:																				Cor	١t
Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24b. MFR CONTROL NO. 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id :				I۷	/. MANUFA	CTUR	RER INF	FORMATI	ION												
701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24.REPORT NULLIFIED 24b. MFR CONTROL NO. YES DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE		RESS OF MANUF	ACTURER					Stu	dy Infor	mat	tion										_
Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447 24.REPORT NULLIFIED 24b. MFR CONTROL NO. YES DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE	·																				
Center No.: Subject Id: 24.REPORT NULLIFIED 24b. MFR CONTROL NO. PYES DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 24b. MFR CONTROL NO. LITERATURE HEALTH PROFESSIONAL DATE OF THIS REPORT 25a. REPORT TYPE	Fort Collins, CO, 80526, UNITED STATES OF AMERICA																				
24.REPORT NULLIFIED 24b. MFR CONTROL NO. DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 24b. MFR CONTROL NO. DO-Tolmar-TLM-2025-00150 24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL 25a. REPORT TYPE	debbie.maierhofer@tolmar.comand+1-4129158447																				
PYES NO DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT DO-Tolmar-TLM-2025-00150 24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL 25a. REPORT TYPE								Sub	oject Id	:											
DO-Tolmar-TLM-2025-00150 24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT DO-Tolmar-TLM-2025-00150 24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL 25a. REPORT TYPE	24.REPORT NULLIFIE	D	24	o. MFR CON	TROL NO.																
24c. DATE RECEIVED BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 24d. REPORT SOURCE STUDY LITERATURE HEALTH PROFESSIONAL 25a. REPORT TYPE	YES	NO	D() Tolmor TI	M 2025 00	1450															
BY MANUFACTURER 03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE	24c. DATE RECEIVED					1130															
03/Apr/2025 DATE OF THIS REPORT 25a. REPORT TYPE				3		OATLIDE	:														
DATE OF THIS REPORT 25a. REPORT TYPE	03/Apr/2025		٦			MIUKE	-														
14/Apr/2025 Initial Followup	DATE OF THIS REPOR	RT	25:																		
	14/Apr/2025		☑	INITIAL	FOLL	OWUP															

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

1a. COUNTRY

DOMINICAN REPUBLIC

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description:

This Invalid case report from Dominican Republic was received Adium via Patient Support Program "ASOFARMA A TU LADO" (reference number: DO-ADIUM-DO-0001-20231229) on 29-Dec-2023 from a consumer (non-healthcare professional) regarding an elderly 84-year-old male patient. This report was assessed as invalid as no adverse event was reported. The reported term "he is half deaf (difficulty hearing)" (no adverse event) was not considered as an adverse event because event started before Eligard was administered.

On 05-Jan-2025, follow up information was received by Adium (reference number: DO-ADIUM-DO-0001-20231229) from a Patient Family Member or friend and sent to Tolmar on 08-JAN-2024. New information included: additional reporter added (patient family member or friend), previously reported medical history and concomitant medication added, new non-serious event of 'high PSA' was added and new lab data added.

The patient's medical history included blood pressure abnormal and current condition included prostate cancer.

Concomitant medication included Candelsal 2.5.

On an unknown date and month in year 2020, the patient began receiving Eligard 22.5 mg every 3 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not reported). No further details were provided.

On 25-Apr-2023, the patient received Eligard 22.5 mg every 3 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not reported). No further details were provided.

On 4-Dec-2023, the patient received Eligard 22.5 mg every 3 months via subcutaneous route for prostate cancer (Lot numbers and Expiration dates were not reported). No further details were provided.

On an unknown date, the patient's daughter reported that the patient was tested for total PSA every month to see if the Eligard medication was having an effect. It was stated that he had to report periodically every month and during the next appointment he would go to the doctor in 14 or 15 days, so every month he must have a PSA test to check how it had gone down and according to the doctor, he would proceed in the way he considered, so that the disease went down and to see how the treatment evolved. The patient did not take any additional medication to Eligard and had been on Eligard treatment for 3 years

Corrective treatment was unknown.

Relevant test results included:

On an unknown date: Prostatic specific antigen: going down (Ref range: not provided).

On 15-Nov-2023: Prostatic specific antigen: 15 ng/ml (Ref range: not provided).

On 01-Dec-2023: Prostatic specific antigen: 9 ng/ml (Ref range: not provided).

Action taken with Eligard in response to the event was dose not changed. De-challenge and Re-challenge were not applicable.

The outcome of prostatic specific antigen increased was recovering.

The reporter did not assess the seriousness of event prostatic specific antigen increased.

The reporter did not provide the causality of prostatic specific antigen increased in relationship to Eligard and Eligard Unspecified Device.

On 03-Apr-2025, the follow up information was received via Adium (reference number: DO-ADIUM-DO-0001-20231229) from a Patient relative (consumer or non-healthcare professional) and sent to Tolmar on 04-Apr-2025. New information included: additional reporter added (patient relative). Case was upgraded from invalid to valid and a new serious event of 'death' (death) was added. Action taken was updated from 'dose not changed' to 'not applicable'. The patient's medical history detail was updated.

The patient's medical history included hypoacusis.

On an unknown date, the patient's relative reported that the patient died. The cause of death was unknown. The patient was 85 years old at the time of his death. It was unknown if an autopsy was performed.

Action taken with Eligard in response to the event was not applicable. De-challenge and Re-challenge were not applicable.

The outcome of death was fatal

Continuation Sheet for CIOMS report

The reporter assessed the seriousness of death as serious (death).

The reporter did not provide the causality of death in relationship to Eligard and Eligard Unspecified Device.

Labeling of previously assessed events is retained as reported in the as determined listedness section of Product event assessment.

Death >Eligard® >unlisted as per CCDS Eligard® > 7-Nov-2024

Death> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025

Death> Eligard®>unlisted as per USPI Eligard®>Feb-2025

Death> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments):

Causality of previously reported event was retained PSA increased: not related to drug and device.

Follow up-Evaluator comment (Tolmar): This is regarding an elderly 84-year-old male patient who reported death (death) during Eligard (Leuprolide acetate) 22.5 mg therapy for prostate cancer. Tolmar assessed death as serious due to fatal outcome. Causal role of Eligard (drug) in patient's death could not be assessed conclusively due to lack of information regarding cause of death, events or circumstances preceding patient's death, autopsy report, relevant medical history, supportive investigations that could indicate cause of death, concomitant medications received by the patient precludes meaningful medical assessment of the report. The event death was assessed as not related to device component of Eligard.

Additional Information (Continuation...)

Lab Result:

Test Name	Test Date	Test Result	Normal Value
BLOOD PRESSURE			
PSA	15/Nov/2023	15 nanogram per millliiter	
PSA	01/Dec/2023	9 nanogram per millliiter	
PSA			

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: BLOOD PRESSURE

Result Unstructured Data (free text): Unknown

Test Date:

4) Test Name: PSA

Result Unstructured Data (free text): going down

Test Date:

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate) Injection, 22.5 milligram (Leuprolide acetate)

Active Substance : 1) Leuprolide acetate

Drug Characterization : Suspect
Form of Admin : 1) Injection

2) Injection3) Injection

Daily Dose : (22.5 milligram(s), 1 in 3 Month)

(22.5 milligram(s), 1 in 3 Month) (22.5 milligram(s), 1 in 3 Month)

Route of Admin : 1) Subcutaneous

2) Subcutaneous

3) Subcutaneous

Indications : 1) Prostate cancer [10060862 - Prostate cancer]

Continuation Sheet for CIOMS report

Therapy Dates : 1) From : 04/Dec/2023 To :Not applicable

2) From : //2020 To :Not applicable

3) From: 25/Apr/2023 To: Not applicable

Action(s) Taken With Drug : Not applicable

Causality

1) Death (Death - 10011906, Death - 10011906)
Causality as per reporter
Causality as per Mfr
DeChallenge
ReChallenge
: Not applicable
ReChallenge
: Not Applicable

2) High PSA (Prostatic specific antigen increased - 10036975, Prostatic specific antigen increased - 10036975)

Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling:

1) Death

CORE UnLabeled

2) High PSA

CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)

Active Substance : 1) Leuprolide acetate

Drug Characterization : Suspect Form of Admin : 1) Injection

Indications : 1) Prostate cancer [10060862 - Prostate cancer]

Action(s) Taken With Drug : Not applicable

Causality

1) Death (Death - 10011906, Death - 10011906)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) High PSA (Prostatic specific antigen increased - 10036975, Prostatic specific antigen increased - 10036975)

Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling:

1) Death

CORE UnLabeled

2) High PSA

CORE UnLabeled

22.CONCOMITANT DRUG(S) (Continuation...)

1). Drug : Candelsal 2.5

Form Strength :

Indications : 1) Product used for unknown indication [10070592 - Product used for unknown indication]

23. OTHER RELEVANT HISTORY (Continuation...)

2) DIFFICULTY HEARING (10048865, Hypoacusis) (Continuing: YES)

3) BLOOD PRESSURE (10005728, Blood pressure abnormal) (Continuing: Unknown)